CLAIMS

1. A compound of Formula I:



(I)

wherein,

R^1 is selected from OR^3, $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5\text{-}C_{10}heteroaryl)$ or a nitrogen atom part of a mono or bicyclic heteroaryl having from 5 to 10 ring members;

R^2 is selected from OR^4, $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5\text{-}C_{10}heteroaryl)$ or a nitrogen atom part of a mono or bicyclic heteroaryl having from 5 to 10 ring members, or R^1 is a covalent bond and R^2 is selected from O, NH, $NC(O)R^5$, $NC(NH)NHR^5$, and $N(C_5\text{-}C_{10}heteroaryl)$ when R^1 and R^2 are taken together with their adjacent atoms to form a heterocycle;

R^3 is selected from hydrogen and a substituted or unsubstituted group selected from $C_1\text{-}C_{12}alkyl$, $C_2\text{-}C_{12}alkenyl$, $C_2\text{-}C_{12}alkynyl$, $C_3\text{-}C_{15}cycloalkyl$, $C_3\text{-}C_{15}heterocycloalkyl$, $C_6\text{-}C_{15}aryl$, and $C_5\text{-}C_{15}heteroaryl$;

R^4 is a substituted or unsubstituted group selected from $C_1\text{-}C_{12}alkyl$, $C_2\text{-}C_{12}alkenyl$, $C_2\text{-}C_{12}alkynyl$, $C_3\text{-}C_{15}cycloalkyl$, $C_3\text{-}C_{15}heterocycloalkyl$, $C_6\text{-}C_{15}aryl$, and $C_5\text{-}C_{15}heteroaryl$; and

R^5 is selected from hydrogen and a substituted or unsubstituted group selected from $C_1\text{-}C_{12}alkyl$, $C_2\text{-}C_{12}alkenyl$, $C_2\text{-}C_{12}alkynyl$, $C_3\text{-}C_{15}cycloalkyl$, $C_3\text{-}C_{15}heterocycloalkyl$, $C_6\text{-}C_{15}aryl$, and $C_5\text{-}C_{15}heteroaryl$;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, wherein said compound is a compound of Formula II:



(II)

wherein,

R^3 is selected from hydrogen and a substituted or unsubstituted group selected from $C_1\text{-}C_{12}alkyl$, $C_2\text{-}C_{12}alkenyl$, $C_2\text{-}C_{12}alkynyl$, $C_3\text{-}C_{15}cycloalkyl$, $C_3\text{-}C_{15}heterocycloalkyl$, $C_6\text{-}C_{15}aryl$, and $C_5\text{-}C_{15}heteroaryl$; and

R^4 is a substituted or unsubstituted group selected from $C_1\text{-}C_{12}alkyl$, $C_2\text{-}C_{12}alkenyl$, $C_2\text{-}C_{12}alkynyl$, $C_3\text{-}C_{15}cycloalkyl$, $C_3\text{-}C_{15}heterocycloalkyl$, $C_6\text{-}C_{15}aryl$, and $C_5\text{-}C_{15}heteroaryl$;

or a pharmaceutically acceptable salt or solvate thereof.

3. The compound of claim 2, wherein R^3 is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{16}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, and C_5-C_{15}heteroaryl.

4. The compound of claim 1 or 2, wherein said compound is a compound of Formula II-A



(II-A)

wherein,

R^4 is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, and C_5-C_{15}heteroaryl;

or a pharmaceutically acceptable salt or solvate thereof.

5. The compound of any one of claims 1 to 4, wherein at least one of R^3 and R^4 is a group of Formula B:



(B)

wherein,

R^6, R^7 and R^8 are each independently a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, C_5-C_{10}heteroaryl, C(O)OH, C(O)OC_1-C_6alkyl, NH_2, NHC(O)OC_1-C_6alkyl, or R^7 and R^8 are taken together with their adjacent carbon atom to form a group selected from C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, or R^6, R^7 and R^8 are taken together with their adjacent carbon atom to form a C_4-C_{10}cycloalkyl or C_4-C_{10}heterocycloalkyl fused ring group, or a C_6-C_{10}aryl, and C_5-C_{10}heteroaryl; and

R^{22} is a hydrogen atom or a group selected from C_1-C_6alkyl, C(O)OH, or C(O)OC_1-C_6alkyl.

6. The compound of claim 5, wherein said R^{22} is C_2-C_6alkyl, or wherein said R^{22} is C_3-C_5alkyl, or wherein said R^{22} is a C_3-C_4alkyl.

7. The compound of claim 5, wherein said group of Formula B is a group of Formula B':



(B')

wherein,

R^6, R^7 and R^8 are each independently a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, C_5-C_{10}heteroaryl, C(O)OH, C(O)OC_1-C_6alkyl, NH_2, NHC(O)OC_1-C_6alkyl, or R^7 and R^8 are taken together with their adjacent carbon atom to form a group selected from C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, or R^6, R^7 and R^8 are taken together with their adjacent carbon atom to form a C_4-C_{10}cycloalkyl or C_4-C_{10}heterocycloalkyl fused ring group, or a C_6-C_{10}aryl, and C_5-C_{10}heteroaryl.

8. The compound of any one of claims 5 to 7, wherein R^6, R^7 and R^8 are each independently a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, and C_5-C_{10}heteroaryl, or R^7 and R^8 are taken together with their adjacent carbon atom to form a group selected from C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, or R^6, R^7 and R^8 are taken together with their adjacent carbon atom to form a C_3-C_8cycloalkyl or C_3-C_8heterocycloalkyl fused ring group, or a C_6-C_{10}aryl, and C_5-C_{10}heteroaryl.

9. The compound of any one of claims 5 to 8, wherein R^6 is a group of Formula C:



(C)

wherein,

R^9 is, separately in each occurrence, selected from hydrogen, hydroxyl, halogen, cyano, trifluoromethyl, nitro, and a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, C(O)OH, C(O)OR^{11}, OR^{11}, OC(O)R^{11}, OC(O)OR^{11}, NHC(O)R^{11}, NH_2, NHR^{11}, and N(R^{11})$_2$;

X is selected from the group consisting of OH, NH_2, NO_2, CN, SH, C(O)OH, C(O)OR^{12}, OC(O)OR^{12}, NHC(O)OR^{12}, SC(O)OR^{12}, P(O)(OH)$_2$, P(O)(OR^{12})$_2$, P(O)(OR^{12})(OH), OC(O)R^{13}, OC(O)NHR^{13}, SC(O)R^{13}, C(O)R^{14}, and NHR^{15};

n is an integer selected from 0, 1, 2 and 3;

R^{11} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl and benzyl;

R^{12} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, benzyl, CH_2R^{16}, and $CH(C_1$-C_6alkyl$)R^{16}$;

R^{13} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, and benzyl;

R^{14} is the residue of a natural or unnatural N-coupled amino acid having an protected or unprotected carboxyl end;

R^{15} is the residue of a natural or unnatural C-coupled amino acid having an protected or unprotected amino end; and

R^{16} is selected from the group consisting of $OC(O)C_1$-C_6alkyl and $OC(O)OC_1$-C_6alkyl.

10. The compound of claim 9, wherein:

R^9 is, separately in each occurrence, selected from hydrogen, hydroxyl, halogen, cyano, trifluoromethyl, nitro, and a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, C(O)OH, $C(O)OR^{11}$, OR^{11}, $OC(O)R^{11}$, $OC(O)OR^{11}$, $NHC(O)R^{11}$, NH_2, NHR^{11}, and $N(R^{11})_2$;

X is selected from the group consisting of OH, NH_2, SH, C(O)OH, $C(O)OR^{12}$, $OC(O)OR^{12}$, $NHC(O)OR^{12}$, $SC(O)OR^{12}$, $OC(O)R^{13}$, $OC(O)NHR^{13}$, $SC(O)R^{13}$, $C(O)R^{14}$, and NHR^{15};

n is an integer selected from 0, 1, 2 and 3;

R^{11} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl and benzyl;

R^{12} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, benzyl, CH_2R^{16}, and $CH(C_1$-C_6alkyl$)R^{16}$;

R^{13} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, and benzyl;

R^{14} is the residue of a natural or unnatural N-coupled amino acid;

R^{15} is the residue of a natural or unnatural C-coupled amino acid; and

R^{16} is selected from the group consisting of $OC(O)C_1$-C_6alkyl and $OC(O)OC_1$-C_6alkyl.

11. The compound of any one of claims 1 to 4, wherein at least one of R^3 and R^4 is a group of Formula D:



(D)

wherein,

R^{17} in each occurrence is each independently a hydrogen atom or a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, C_5-C_{10}heteroaryl, an electron-withdrawing group or a substituent selected from the group consisting of amino, amido, hydroxyl, alkoxy, acyloxy, alkoxycabonyloxy, and the like; and

m is an integer from 1 to 5.

12. The compound of any one of claims 1 to 4, wherein at least one of R^3 and R^4 is a group of Formula E:



(E)

wherein,

R^z is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, C_5-C_{15}heteroaryl, OC_1-C_{12}alkyl, OC_2-C_{12}alkenyl, OC_2-C_{12}alkynyl, OC_3-C_{15}cycloalkyl, OC_3-OC_{16}heterocycloalkyl, OC_6-C_{15}aryl, and OC_5-C_{15}heteroaryl.

13. The compound of any one of claims 1 to 4, wherein at least one of R^3 and R^4 is a group of Formula F:



(F)

wherein,

W-Y-Z is selected from $C(O)OCH_2$, $OC(O)CH_2$, $CH_2C(O)O$, and $CH_2OC(O)$;

R^w, R^x, and R^y are each independently selected from a hydrogen atom or a substituted or unsubstituted C_1-C_3alkyl group, or R^w and R^x are taken together with their adjacent carbon atoms to form a double bond; and

k is an integer selected from 0, 1 and 2.

14. The compound of claim 4, wherein said compound is selected from Compounds A1 to A73 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

15. The compound of claim 3, wherein said compound is selected from Compounds B1 to B87 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

16. The compound of 1, wherein said compound is selected from Compounds C1 to C3 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

17. The compound of claim 12, wherein said compound is selected from Compounds D1 to D8 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

18. The compound of claim 17, wherein said compound is Compound D5, or a pharmaceutically acceptable salt or solvate thereof.

19. The compound of claim 12, wherein said compound is selected from Compounds Compounds A71, A72, A73, B76, B77, B78, B79, B80 and B81 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

20. The compound of claim 19, wherein said compound is selected from Compounds B76 and B77, or a pharmaceutically acceptable salt or solvate thereof.

21. A compound of Formula III:

$$A-(L^x-A)_p-L^x-A \qquad (III)$$

wherein,

A is 1,3-propanedisulfonic acid moiety;

L^x is a cleavable linkage for covalently and dissociably coupling together two 1,3PDS moieties respectively; and

p is 0 or an integer selected from 1, 2, 3, 4, or 5;

or a pharmaceutically acceptable salt, ester, or solvate thereof.

22. The compound of claim 19, wherein said compound is a compound of Formula III-A:

$$L^y(A)_m \qquad (III\text{-}A)$$

wherein,

m is an integer from 2 to 5;

A is 1,3-propanedisulfonic acid moiety; and

L^y is a multivalent carrier moiety for covalently and dissociably coupling from two to five A moieties, at either sulfonic acid end of A;

or a pharmaceutically acceptable salt, ester, or solvate thereof.

23. The compound of claim 21 or 22, wherein said compound is selected from Compounds G1 to G4 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

24. The compound of claim 1, wherein said compound is a compound of Formula IV:



(IV)

wherein,

R^{18} is selected from OR^3, NH_2, $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5-C_{10}$heteroaryl), $-NR^{20}R^{21}$, R^{14}, and $-NHR^{15}$;

R^{19} is selected from NH_2, $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5-C_{10}$heteroaryl), $-NR^{20}R^{21}$, R^{14}, and $-NHR^{15}$;

R^3, R^5, R^{14}, and R^{15} are as defined in any one of the preceding claims; and

R^{20} and R^{21} are taken together with their adjacent nitrogen atom to form a mono or bicyclic heteroaryl having from 5 to 10 ring members;

or a pharmaceutically acceptable salt or solvate thereof.

25. The compound of claim 22, wherein:

R^{18} is selected from OR^3, $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5-C_{10}$heteroaryl) and $-NR^{20}R^{21}$;

R^{19} is selected from $-NHC(O)R^5$, $-NHC(NH)NHR^5$, $-NH(C_5-C_{10}$heteroaryl) and $-NR^{20}R^{21}$;

R^3 and R^5 are as defined in any one of the preceding claims; and

R^{20} and R^{21} are taken together with their adjacent nitrogen atom to form a mono or bicyclic heteroaryl having from 5 to 10 ring members;

or a pharmaceutically acceptable salt or solvate thereof.

26. The compound of claim 22 or 23, wherein said compound is selected from Compounds N1 to N18 as herein described, or a pharmaceutically acceptable salt or solvate thereof.

27. A compound or a pharmaceutically acceptable salt or solvate thereof substantially as herein described with reference to any one or more of the examples.

28. A compound of the formula:



or a pharmaceutically acceptable salt or solvate thereof.

29. A pharmaceutical composition comprising a compound according to any one of claims 1 to 28 together with a pharmaceutically acceptable carrier.

30. Use of a compound of any one of claims 1 to 28, for treating or preventing amyloid A amyloidosis.

31. Use of a compound of any one of claims 1 to 28, for treating a renal disorder or for stabilizing renal function or delaying progression of a renal disorder.

32. Use of a compound of any one of claims 1 to 28, for delaying requirement for dialysis in a patient with a renal disorder.

33. The use of claim 31 or 32, wherein said renal disorder is diabetic nephropathy.

34. The use of claim 31 or 32, wherein said renal disorder is amyloid A amyloidosis.

35. Use of a compound of any one of claims 1 to 28, for the treatment or prevention of dyslipidemia or metabolic syndrome.

36. Use of a compound of any one of claims 1 to 28, for the prevention or treatment of hyperglycemia.

37. The use of claim 36, wherein the disease is diabetes mellitus.

38. The use of claim 37, wherein said diabetes mellitus is type 1 diabetes.

39. The use of claim 37, wherein said diabetes mellitus is type 2 diabetes.

40. The use of claim 39, wherein said diabetes mellitus is type 2 diabetes with features of metabolic syndrome.

41. Use of a compound of any one of claims 1 to 28 for increasing insulin levels circulating in blood in response to food, decreasing resistance to insulin and/or increasing insulin sensitivity in selected tissues (e.g. fat, muscle and liver), increasing insulin secretion by pancreatic cells, increasing beta-cells and/or islets of Langerhans neogenesis and/or regeneration of islets of Langerhans or preventing their destruction by apoptosis, preventing apoptosis in beta-cells, and stabilizing, restoring, and/or improving pancreatic function, and more particularly stabilizing, restoring, and/or improving beta-cells size, growth and/or function.

42. Use of a compound of any one of claims 1 to 28 for delaying the requirement for treating a diabetic patient with exogenous insulin.

43. A method for treating or preventing AA amyloidosis, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 28 such that said AA amyloidosis is treated or prevented.

44. A method for treating a renal disorder or for stabilizing renal function or delaying progression of a renal disorder, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 28, such that said renal disorder is treated, said renal function is stabilized or progression of said renal disorder delayed.

45. The method of claim 44, whereln said renal disorder is diabetic nephropathy.

46. A method for the treatment or prevention of dyslipidemia or metabolic syndrome, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 28, such that said dyslipidemia or metabolic syndrome is treated or prevented.

47. A method for the treatment or prevention of hyperglycemia, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 25, such that said hyperglycemia is treated or prevented.

48. The method of claim 47, wherein the disease is diabetes mellitus.

49. The method of claim 48, wherein said diabetes mellitus is type 1 diabetes.

50. The method of claim 48, wherein said diabetes mellitus is type 2 diabetes.

51. The method of claim 50, wherein said diabetes mellitus is type 2 diabetes with features of metabolic syndrome.

52. A method for increasing insulin levels circulating in blood in response to food, decreasing resistance to insulin and/or increasing insulin sensitivity in selected tissues (e.g. fat, muscle and liver), increasing insulin secretion by pancreatic cells, increasing beta-cells and/or islets of Langerhans neogenesis and/or regeneration of islets of Langerhans or preventing their destruction by apoptosis, preventing apoptosis in beta-cells, and stabilizing, restoring, and/or improving pancreatic function, and more particularly stabilizing, restoring, and/or improving beta-cells size, growth and/or function, comprising administering a therapeutically effective amount of a compound of any one of claims 1 to 28 to a subject in need thereof.

53. Method for delaying the requirement for treating a diabetic patient with exogenous insulin, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 28, such that said requirement is delayed.

54. Use of a therapeutic compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament; a pharmaceutical composition; use of a pharmaceutical composition to treat diabetes; a compound; use of a pharmaceutical composition in the manufacture of a medicament for treating or preventing AA amyloidosis; a method of treating or preventing AA amyloidosis; or use of a pharmaceutical composition in the manufacture of a medicament for treating diabetes, substantially as herein described.

55. A method for the preparation of a compound of Formula II-A as defined in any one of claims 4 to 10, comprising the steps of: a) preparing a disulfonyl chloride of the formula: ClO_2S-$(CH_2)_3$-SO_2Cl; b) reacting the disulfonyl chloride of step (a) with a compound of the formula PGOH, wherein said PG is a protecting group, to produce a monosulfonyl chloride of the formula: PGO_3S-$(CH_2)_3$-SO_2Cl; c) reacting the monosulfonyl chloride of step (b) with an alcohol of the formula R^4OH to produce a monoprotected compound of the

formula: PGO_3S-$(CH_2)_3$-SO_3OR^4; and d) cleaving the protecting group of the monoprotected compound of step (c) to produce a compound of Formula II-A.

56. The method of claim 55, wherein step (a) comprises reacting 1,3-propanedisulfonic acid disodium salt with phosphorus pentachloride.

57. The method of claims 55 or 56, wherein the PGOH compound of step (b) is phenol and step (d) comprises reacting the monoprotected compound with a source of palladium and a source of hydrogen gas.

58. The method of claim 57, wherein step (d) comprises adding palladium hydroxide ($Pd(OH)_2$), an acid and hydrogen gas.

59. The method of claim 58, wherein said acid is acetic acid.

60. The method of any one of claims 55 to 59, wherein steps (b) and (c) further comprise addition of a base.

61. The method of claim 60, wherein said base is an organic base

62. The method of claim 61, wherein said organic base is pyridine.

CLAIMS

1. A compound of Formula II:



(II)

wherein,

R^3 is selected from hydrogen and a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, and C_5-C_{15}heteroaryl; and

R^4 is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, and C_5-C_{15}heteroaryl; and

wherein at least one of R^3 and R^4 is a group selected from Formula B, E and F:



(B);



(E); and



(F);

wherein,

R^6, R^7 and R^8 are each independently NH_2 or a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, C_5-C_{10}heteroaryl, $NHC(O)OC_1$-C_6alkyl, or R^7 and R^8 are taken together with their adjacent carbon atom to form a group selected from C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, or R^6, R^7 and R^8 are taken together with their adjacent carbon atom to form a C_4-C_{10}cycloalkyl fused ring group, a C_4-C_{10}heterocycloalkyl fused ring group, or a C_5-C_{10}heteroaryl; or R^6 is a group of Formula C:



(C)

wherein,

R^9 is, separately in each occurrence, selected from hydrogen, hydroxyl, halogen, cyano, trifluoromethyl, nitro, C(O)OH, $C(O)OR^{11}$, OR^{11}, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, $NHC(O)R^{11}$, NHR^{11}, $N(R^{11})_2$, and a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, and C_5-C_6heteroaryl;

X is selected from the group consisting of OH, NH_2, NO_2, CN, SH, C(O)OH, $C(O)OR^{12}$, $OC(O)OR^{12}$, $NHC(O)OR^{12}$, $SC(O)OR^{12}$, $P(O)(OH)_2$, $P(O)(OR^{12})_2$, $P(O)(OR^{12})(OH)$, $OC(O)R^{13}$, $OC(O)NHR^{13}$, $SC(O)R^{13}$, $C(O)R^{14}$, and NHR^{15};

n is an integer selected from 1 , 2 and 3;

R^{11} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl and benzyl;

R^{12} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, benzyl, CH_2R^{16}, and $CH(C_1$-C_6alkyl)R^{16};

R^{13} is a substituted or unsubstituted group selected from C_1-C_6alkyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6aryl, C_5-C_6heteroaryl, and benzyl;

R^{14} is the residue of a natural amino acid coupled through its amino group and having a protected or unprotected carboxyl end;

R^{15} is the residue of a natural amino acid coupled through its carboxyl group and having a protected or unprotected amino end;

R^{16} is selected from the group consisting of $OC(O)C_1$-C_6alkyl and $OC(O)OC_1$-C_6alkyl;

R^{22} is a hydrogen atom or a group selected from C_1-C_6alkyl, C(O)OH, or $C(O)OC_1$-C_6alkyl;

R^w, R^x, and R^y are each independently selected from a hydrogen atom or a substituted or unsubstituted C_1-C_3alkyl group, or R^w and R^x are taken together with their adjacent carbon atoms to form a double bond;

R^z is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, C_5-C_{15}heteroaryl, OC_1-C_{12}alkyl, OC_2-C_{12}alkenyl, OC_2-C_{12}alkynyl, OC_3-C_{15}cycloalkyl, OC_3-OC_{15}heterocycloalkyl, OC_6-C_{15}aryl, and OC_5-C_{15}heteroaryl;

W-Y-Z is selected from $C(O)OCH_2$, $OC(O)CH_2$, $CH_2C(O)O$, and $CH_2OC(O)$;

k is an integer selected from 0, 1 and 2;

wherein when both of R^3 and R^4 are substituted branched C_3-C_8alkyl groups, then said branched C_3-C_8alkyl is substituted by a substituent other than aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^3 is a substituted or unsubstituted group selected from C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}alkynyl, C_3-C_{15}cycloalkyl, C_3-C_{15}heterocycloalkyl, C_6-C_{15}aryl, and C_5-C_{15}heteroaryl.

3. The compound of claim 1, wherein said R^3 is hydrogen, or a pharmaceutically acceptable salt thereof.

4. The compound of any one of claims 1 to 3, wherein R^4 is a group of Formula B.

5. The compound of claim 1, wherein R^3 and R^4 are each a group of Formula B.

6. The compound of claim 4 or 5, wherein said R^{22} is C_2-C_6alkyl, or wherein said R^{22} is C_3-C_5alkyl, or wherein said R^{22} is a C_3-C_4alkyl.

7. The compound of claim 4 or 5, wherein said R^{22} is hydrogen.

8. The compound of any one of claims 4 to 7, wherein R^6, R^7 and R^8 are each independently a substituted or unsubstituted group selected from C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, C_6-C_{10}aryl, and C_5-C_{10}heteroaryl, or R^7 and R^8 are taken together with their adjacent carbon atom to form a group selected from C_3-C_8cycloalkyl, and C_3-C_8heterocycloalkyl, or R^6, R^7 and R^8 are taken together with their adjacent carbon atom to form a C_4-C_8cycloalkyl fused ring group, a C_4-C_8heterocycloalkyl fused ring group, or a C_5-C_{10}heteroaryl.

9. The compound of any one of claims 1 to 7, wherein R^6 is a group of Formula C in which:

X is selected from the group consisting of OH, NH_2, SH, C(O)OH, $C(O)OR^{12}$, $OC(O)OR^{12}$, $NHC(O)OR^{12}$, $SC(O)OR^{12}$, $OC(O)R^{13}$, $OC(O)NHR^{13}$, $SC(O)R^{13}$, $C(O)R^{14}$, and NHR^{15}.

10. The compound of any one of claims 1 to 3, wherein R^4 is a group of Formula E.

11. The compound of claim 1, wherein R^3 and R^4 are each a group of Formula E.

12. The compound of any one of claims 1 to 3, wherein R^4 is a group of Formula F.

13. The compound of claim 1, wherein R^3 and R^4 are each a group of Formula F.

14. The compound of claim 1, wherein said compound is selected from:



Compound A1



Compound A2



Compound A3



Compound A4



Compound A6



Compound A9



Compound A13



Compound A14



Compound A15



Compound A16



Compound A17



Compound A18



Compound A19



Compound A20



Compound A21



Compound A22



Compound A23



Compound A24



Compound A25



Compound A26



Compound A27



Compound A28



Compound A31



Compound A33



Compound A34



Compound A35



Compound A36



Compound A37



Compound A38



Compound A39



Compound A40



Compound A41



Compound A42



Compound A43



Compound A44



Compound A45



Compound A46



Compound A47



Compound A48



Compound A49



Compound A50



Compound A51



Compound A52



Compound A53



Compound A54



Compound A56



Compound A57



Compound A64



Compound A65



Compound A66



Compound A67



Compound A68



Compound A69



Compound A70



Compound A71



Compound A72



Compound A73



Compound B1



Compound B2



Compound B3



Compound B4



Compound B6



Compound B9



Compound B13



Compound B14



Compound B15



Compound B16



Compound B17



Compound B18



Compound B19



Compound B20



Compound B21



Compound B22



Compound B23



Compound B24



Compound B25



Compound B26



Compound B27



Compound B28



Compound B31



Compound B33



Compound B34



Compound B35



Compound B36



Compound B37



Compound B38



Compound B39



Compound B40



Compound B41



Compound B42



Compound B43



Compound B44



Compound B45



Compound B46



Compound B47



Compound B48



Compound B49



Compound B50



Compound B51



Compound B52



Compound B53



Compound B54



Compound B56



Compound B57



Compound B73



Compound B74



Compound B75





Compound B76



Compound B77



Compound B78



Compound B79



Compound B80

Compound B81

Compound B82



Compound D1



Compound D2



Compound D3



Compound D4



Compound D5



Compound D6



Compound D7



Compound D8;



or a pharmaceutically acceptable salt thereof.

15. The compound of claim 14, wherein said compound is Compound D5.

16. The compound of claim 14, wherein said compound is selected from Compounds A71, A72, A73, B76, B77, B78, B79, B80, B81, and pharmaceutically acceptable salts thereof.

17. The compound of claim 16, wherein said compound is Compound B76 or Compound B77.

18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 together with a pharmaceutically acceptable carrier.

19. Use of a compound of any one of claims 1 to 17, in the manufacture of a medicament for treating a renal disorder, or for stabilizing renal function or delaying progression of a renal disorder.

20. The use of claim 19, wherein said renal disorder is diabetic nephropathy.

21. The use of claim 19, wherein said renal disorder is amyloid A amyloidosis.

22. Use of a compound of any one of claims 1 to 17, in the manufacture of a medicament for the treatment or prevention of dyslipidemia, metabolic syndrome and/or diabetes mellitus.

23. The use of claim 22, wherein said diabetes mellitus is type 1 diabetes.

24. The use of claim 22, wherein said diabetes mellitus is type 2 diabetes.

25. The use of claim 22, wherein said diabetes mellitus is type 2 diabetes with features of metabolic syndrome.

26. A method for the preparation of a compound of as defined in claim 3, comprising the steps of:

a) reacting a disulfonyl chloride of the formula: ClO_2S-$(CH_2)_3$-SO_2Cl with a compound of the formula PGOH in the presence of a base, wherein said PG is a

protecting group, to produce a monosulfonyl chloride of the formula: PGO_3S-$(CH_2)_3$-SO_2Cl;

b) reacting the monosulfonyl chloride of step (a) with an alcohol of the formula R^4OH in the presence of a base, to produce a monoprotected compound of the formula: PGO_3S-$(CH_2)_3$-SO_3R^4; and

c) cleaving the protecting group of the monoprotected compound of step (b) to produce a compound of the formula: HO_3S-$(CH_2)_3$-SO_3R^4, or a pharmaceutically acceptable salt thereof.

27. The method of claim 26, wherein the disulfonyl chloride of step (a) is prepared by reacting 1,3-propanedisulfonic acid disodium salt with phosphorus pentachloride.

28. The method of claims 26 or 27, wherein the PGOH compound of step (a) is phenol and step (c) comprises reacting the monoprotected compound with a source of palladium and a source of hydrogen gas.

29. The method of claim 28, wherein step (c) comprises adding palladium hydroxide ($Pd(OH)_2$), an acid and hydrogen gas.

30. The method of claim 29, wherein said acid is acetic acid.

31. The method of any one of claims 26 to 30, wherein the base in step (a) and/or (b) is an organic base.

32. The method of claim 31, wherein said organic base is pyridine.